Implementation of newborn screening for mucopolysaccharidosis type IVA and long-term monitoring in Taiwan

被引：1

作者：

Lin, Hsiang-Yu ^{[1
,2
,3
,4
,5
,6
]}

Lee, Chung-Lin ^{[1
,2
,3
,4
,5
]}

Chang, Ya-Hui ^{[1
,3
]}

Tu, Yuan-Rong ^{[2
]}

Lo, Yun-Ting ^{[3
]}

Wu, Jun-Yi ^{[3
]}

Niu, Dau-Ming ^{[7
]}

Liu, Mei-Ying ^{[8
]}

Liu, Hsin-Yun ^{[8
]}

Chen, Hsiao-Jan ^{[8
]}

Kao, Shu-Min ^{[8
]}

Wang, Li-Yun ^{[9
]}

Ho, Huey-Jane ^{[9
]}

Chuang, Chih-Kuang ^{[2
,10
]}

Lin, Shuan-Pei ^{[1
,2
,3
,4
,11
]}

机构：

[1] MacKay Mem Hosp, Dept Pediat, 92 Sec 2,Chung Shan North Rd, Taipei 10449, Taiwan

[2] MacKay Mem Hosp, Dept Med Res, 92 Chung Shan N Rd,Sec 2, Taipei 10449, Taiwan

[3] MacKay Mem Hosp, Rare Dis Ctr, Taipei, Taiwan

[4] MacKay Med Coll, Dept Med, New Taipei City, Taiwan

[5] MacKay Jr Coll Med Nursing & Management, Taipei, Taiwan

[6] China Med Univ, China Med Univ Hosp, Dept Med Res, Taichung, Taiwan

[7] Taipei Vet Gen Hosp, Dept Pediat, Taipei, Taiwan

[8] Chinese Fdn Hlth, Neonatal Screening Ctr, Taipei, Taiwan

[9] Taipei Inst Pathol, Neonatal Screening Ctr, Taipei, Taiwan

[10] Fu Jen Catholic Univ, Coll Med, Taipei, Taiwan

[11] Natl Taipei Univ Nursing & Hlth Sci, Dept Infant & Child Care, Taipei, Taiwan

来源：

GENETICS IN MEDICINE | 2024年 / 26卷 / 12期

关键词：

Enzyme replacement therapy; Genotype-phenotype correlation; Glycosaminoglycans; Mucopolysaccharidosis IVA; (MPS IVA); Newborn screening program; STEM-CELL TRANSPLANTATION; ELOSULFASE ALPHA; MORQUIO;

D O I：

10.1016/j.gim.2024.101286

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Purpose: Mucopolysaccharidosis IVA (MPS IVA) is a rare lysosomal storage disorder arising from a deficiency in N-acetylgalactosamine-6-sulfatase. Methods: From September 2019 to October 2023, a total of 264,843 Taiwanese newborns underwent screening for MPS IVA using dried blood spots and tandem mass spectrometry. Results: Among the 95 referred infants, 9 (9%) were confirmed to have MPS IVA (group 1), 18 (19%) were highly suspected to have MPS IVA (group 2), 61 (64%) were identified as heterozygotes of MPS IVA (group 3), and 7 (7%) were determined not to have MPS IVA (group 4). A total of 34 different GALNS (HGNC:4122) gene variants were identified through our MPS IVA newborn screening program. The most prevalent variant was c.857C>T p.(Thr286Met), found in 33 cases (29%), followed by c.953T>G p.(Met318Arg) in 22 cases (19%). Intravenous enzyme replacement therapy was initiated in 5 patients at ages ranging from 0.3 to 1.7 years. The estimated incidence of MPS IVA in this screening program was 3.4 per 100,000 live births. Conclusion: Because of the progressive nature of MPS IVA, an early diagnosis facilitated by newborn screening and prompt initiation of enzyme replacement therapy before irreversible organ damage occurs may result in improved clinical outcomes.

引用

页数：20

共 50 条

[21] Long-term cardiovascular outcomes and mortality with enzyme replacement therapy in patients with mucopolysaccharidosis type II [J].

Kwak, Ji Hee ;

Choi, Yong Jun ;

Kim, Sinae ;

Yang, Aram .

JOURNAL OF INHERITED METABOLIC DISEASE, 2025, 48 (01)

[22] Long-Term Outcomes of Early Enzyme Replacement Therapy for Mucopolysaccharidosis IV: Clinical Case Studies of Two Siblings [J].

Barak, Sharon ;

Anikster, Yair ;

Sarouk, Ifat ;

Stern, Eve ;

Eisenstein, Etzyona ;

Yissar, Tamar ;

Sherr-Lurie, Nir ;

Raas-Rothschild, Annick ;

Guttman, Dafna .

DIAGNOSTICS, 2020, 10 (02)

[23] Long-term Efficacy and Safety of Laronidase in the Treatment of Mucopolysaccharidosis I [J].

Clarke, Lorne A. ;

Wraith, J. Edmond ;

Beck, Michael ;

Kolodny, Edwin H. ;

Pastores, Gregory M. ;

Muenzer, Joseph ;

Rapoport, David M. ;

Berger, Kenneth I. ;

Sidman, Marisa ;

Kakkis, Emil D. ;

Cox, Gerald F. .

PEDIATRICS, 2009, 123 (01) :229-240

[24] Inflammatory process and oxidative/nitrative stress: in vivo study in mucopolysaccharidosis type IV A patients under long-term enzyme replacement therapy [J].

Delgado, Camila Aguilar ;

Hammerschmidt, Tatiane ;

Faverzini, Jessica Lamberty ;

Lopes, Franciele ;

Giugliani, Roberto ;

Baldo, Guilherme ;

Vargas, Carmen Regla .

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2023, 737

[25] The combined use of enzyme activity and metabolite assays as a strategy for newborn screening of mucopolysaccharidosis type I [J].

Polo, Giulia ;

Gueraldi, Daniela ;

Giuliani, Antonella ;

Rubert, Laura ;

Cazzorla, Chiara ;

Salviati, Leonardo ;

Marzollo, Antonio ;

Biffi, Alessandra ;

Burlina, Alessandro P. ;

Burlina, Alberto B. .

CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2020, 58 (12) :2063-2072

[26] A long term follow-up study of the development of hip disease in Mucopolysaccharidosis type VI [J].

Oussoren, Esmee ;

Bessems, Johannes H. J. M. ;

Pollet, Virginie ;

van der Meijden, Jan C. ;

van der Giessen, Lianne J. ;

Plug, Iris ;

Devos, Annick S. ;

Ruijter, George J. G. ;

van der Ploeg, Ans T. ;

Langeveld, Mirjam .

MOLECULAR GENETICS AND METABOLISM, 2017, 121 (03) :241-251

[27] Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: A case series [J].

Lin, Hsiang-Yu ;

Chuang, Chih-Kuang ;

Wang, Chung-Hsing ;

Chien, Yin-Hsiu ;

Wang, Yu-Mei ;

Tsai, Fuu-Jen ;

Chou, Yen-Yin ;

Lin, Shio Jean ;

Pan, Hui-Ping ;

Niu, Dau-Ming ;

Hwu, Wuh-Liang ;

Ke, Yu-Yuan ;

Lin, Shuan-Pei .

MOLECULAR GENETICS AND METABOLISM REPORTS, 2016, 7 :63-69

[28] Experiences of parents and patients with the timing of Mucopolysaccharidosis type I (MPS I) diagnoses and its relevance to the ethical debate on newborn screening [J].

de Ru, Minke H. ;

Bouwman, Machtelt G. ;

Wijburg, Frits A. ;

van Zwieten, Myra C. B. .

MOLECULAR GENETICS AND METABOLISM, 2012, 107 (03) :501-507

[29] The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII [J].

Wang, Raymond Y. ;

da Silva Franco, Jose Francisco ;

Lopez-Valdez, Jaime ;

Martins, Esmeralda ;

Sutton, Vernon Reid ;

Whitley, Chester B. ;

Zhang, Lin ;

Cimms, Tricia ;

Marsden, Deborah ;

Jurecka, Agnieszka ;

Harmatz, Paul .

MOLECULAR GENETICS AND METABOLISM, 2020, 129 (03) :219-227

[30] Incorporation of Second-Tier Biomarker Testing Improves the Specificity of Newborn Screening for Mucopolysaccharidosis Type I [J].

Peck, Dawn S. ;

Lacey, Jean M. ;

White, Amy L. ;

Pino, Gisele ;

Studinski, April L. ;

Fisher, Rachel ;

Ahmad, Ayesha ;

Spencer, Linda ;

Viall, Sarah ;

Shallow, Natalie ;

Siemon, Amy ;

Hamm, J. Austin ;

Murray, Brianna K. ;

Jones, Kelly L. ;

Gavrilov, Dimitar ;

Oglesbee, Devin ;

Raymond, Kimiyo ;

Matern, Dietrich ;

Rinaldo, Piero ;

Tortorelli, Silvia .

INTERNATIONAL JOURNAL OF NEONATAL SCREENING, 2020, 6 (01)

← 1 2 3 4 5 →